Van Oene Mark 4

What Happened
Mark Van Oene, Chief Operating Officer of Pacific Biosciences (PACB), sold 129,790 shares on 2026-02-17 and 55,107 shares on 2026-02-18, for reported proceeds of $204,549 and $89,769 respectively (total 184,897 shares for ~$294,318). The transactions are reported as sales (open market/private sale). Footnote F1 states these sales include shares mandatorily sold to cover tax withholding in connection with RSU vesting.

Key Details

• Transaction dates & prices:
  • 2026-02-17: 129,790 shares at a weighted average $1.58 (filing notes sale prices ranged $1.51–$1.68) — $204,549.
  • 2026-02-18: 55,107 shares at a weighted average $1.63 (filing notes sale prices ranged $1.55–$1.70) — $89,769.
• Total sold: 184,897 shares for ~$294,318.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Shares mandatorily sold to cover tax withholding for RSU vesting.
  • F2 / F4: Reported sale prices are weighted averages across price ranges; issuer or filer can provide per-price breakdown on request.
  • F3: Notes inclusion of 7,500 shares purchased under the company ESPP on 2025-09-02.
• Filing timeliness: Reported transaction date 2026-02-17; Form 4 filed 2026-02-19 (within the typical 2-business-day window).

Context
These were sales — including tax-withholding sales tied to RSU vesting — which are common and do not necessarily signal a change in executive confidence. For retail investors, purchases by insiders often convey clearer bullish signals; this filing documents routine liquidity/tax-related sales rather than an acquisition or exercise-based change in ownership.